{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:50:49Z","timestamp":1791280249187,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.eururo.2011.09.026","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T23:53:03Z","timestamp":1318549983000},"page":"128-145","source":"Crossref","is-referenced-by-count":155,"title":["Markers Predicting Response to Bacillus Calmette-Gu\u00e9rin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review"],"prefix":"10.1016","volume":"61","author":[{"given":"Tahlita C.M.","family":"Zuiverloon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke J.M.","family":"Nieuweboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"V\u00e9kony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.","family":"Kirkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H.","family":"Bangma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen C.","family":"Zwarthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.09.026_bib0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Gu\u00e9rin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Gu\u00e9rin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0025","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Gu\u00e9rin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.09.026_bib0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Gu\u00e9rin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0040","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/end.2010.0319","article-title":"Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer","volume":"24","author":"Ali","year":"2010","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer","volume":"106","author":"Van Rhijn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.09.026_bib0050","first-page":"514","article-title":"A prospective evaluation of second transurethral resection in non-muscle invasive bladder tumors","volume":"15","author":"Aydin","year":"2010","journal-title":"J BUON"},{"key":"10.1016\/j.eururo.2011.09.026_bib0055","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0065","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Gu\u00e9rin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0075","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1464-410X.2003.04764.x","article-title":"Bacillus Calmette-Gu\u00e9rin therapy in stage Ta\/T1 bladder cancer: prognostic factors for time to recurrence and progression","volume":"93","author":"Andius","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.09.026_bib0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00365590410028692","article-title":"Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Gu\u00e9rin","volume":"38","author":"Andius","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0085","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Gu\u00e9rin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2003.11.011","article-title":"Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1\u2013S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1)","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to bacillus Calmette-Gu\u00e9rin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.09.026_bib0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.09.026_bib0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette-Gu\u00e9rin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2011.09.026_bib0125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","article-title":"Role of fibronectin in intravesical BCG therapy for superficial bladder cancer","volume":"139","author":"Ratliff","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0130","first-page":"1762","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Gu\u00e9rin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.matbio.2005.06.008","article-title":"Fibronectin fibrillogenesis, a cell-mediated matrix assembly process","volume":"24","author":"Mao","year":"2005","journal-title":"Matrix Biol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0140","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.juro.2009.06.026","article-title":"Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Gu\u00e9rin for bladder urothelial cancer","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","article-title":"Activation of natural killer cells by bacillus Calmette-Gu\u00e9rin","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0150","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0155","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Gu\u00e9rin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urolonc.2007.11.031","article-title":"Role of neutrophils in BCG immunotherapy for bladder cancer","volume":"26","author":"Simons","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0165","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective bacillus Calmette-Gu\u00e9rin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0170","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Gu\u00e9rin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.09.026_bib0180","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1464-410X.2004.05176.x","article-title":"Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?","volume":"94","author":"Beatty","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.09.026_bib0185","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of bacille Calmette-Gu\u00e9rin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.09.026_bib0190","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","article-title":"Inflammatory cell infiltration of tumors: Jekyll or Hyde","volume":"26","author":"Talmadge","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.eururo.2011.09.026_bib0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ijc.10915","article-title":"Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas","volume":"104","author":"Iwamoto","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0215","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9440(10)64255-1","article-title":"Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis","volume":"161","author":"Schoppmann","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0220","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Gu\u00e9rin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2011.09.026_bib0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"De Reijke","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0235","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0240","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0245","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","article-title":"Interleukin-8 expression in the urine after bacillus Calmette-Gu\u00e9rin therapy: a potential prognostic factor of tumor recurrence and progression","volume":"158","author":"Thalmann","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0250","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)64361-3","article-title":"Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Gu\u00e9rin (modified Danish 1331 strain) for superficial bladder cancer","volume":"168","author":"Kumar","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0255","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.3816\/CGC.2009.n.016","article-title":"Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Gu\u00e9rin treatment in non-muscle-invasive bladder tumors","volume":"7","author":"Sagnak","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0260","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0022-5347(01)64111-9","article-title":"Urinary interleukin-8\/creatinine level as a predictor of response to intravesical bacillus Calmette-Gu\u00e9rin therapy in bladder tumor patients","volume":"158","author":"Rabinowitz","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0265","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Gu\u00e9rin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0270","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2011.09.026_bib0275","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0952-7915(94)90119-8","article-title":"Tumor necrosis factor receptor superfamily members and their ligands","volume":"6","author":"Armitage","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0280","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Gu\u00e9rin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0285","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","article-title":"Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) results in the release of functional soluble TRAIL\/Apo-2L","volume":"106","author":"Kemp","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.eururo.2011.09.026_bib0290","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/01.ju.0000091826.83705.79","article-title":"Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Gu\u00e9rin determine the succeeding Th1 response","volume":"170","author":"De Boer","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0295","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0300","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-5347(01)63731-5","article-title":"Correlation between p53 over expression and response to bacillus Calmette-Gu\u00e9rin therapy in a high risk select population of patients with T1G3 bladder cancer","volume":"159","author":"Lebret","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0305","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0090-4295(01)01551-5","article-title":"Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Gu\u00e9rin therapy","volume":"59","author":"Peyromaure","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.09.026_bib0310","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5347(01)61770-1","article-title":"Correlation and prognostic significance of p53, p21WAF1\/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Gu\u00e9rin intravesical therapy","volume":"161","author":"Zlotta","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0315","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2003.11.018","article-title":"Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin (BCG)","volume":"45","author":"Saint","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0320","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Gu\u00e9rin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0325","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000020233","article-title":"Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer","volume":"37","author":"Lebret","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0330","first-page":"4201","article-title":"Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer","volume":"29","author":"Cormio","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0335","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/carcin\/24.3.505","article-title":"XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity","volume":"24","author":"Wu","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.eururo.2011.09.026_bib0340","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","article-title":"An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer","volume":"94","author":"Bosken","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.09.026_bib0345","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.11109","article-title":"Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability","volume":"105","author":"Catto","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2011.09.026_bib0350","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/1078-0432.CCR-04-1101","article-title":"Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer","volume":"11","author":"Gu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0355","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4161\/cbt.7.5.5763","article-title":"XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy","volume":"7","author":"Mittal","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.eururo.2011.09.026_bib0360","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12032-009-9187-y","article-title":"Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India","volume":"27","author":"Gangawar","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0365","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00432-009-0717-y","article-title":"XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy","volume":"136","author":"Gangwar","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0370","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2008.02.015","article-title":"Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Gu\u00e9rin immunotherapy in bladder cancer","volume":"184","author":"Ahirwar","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.eururo.2011.09.026_bib0380","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1464-410X.2009.08549.x","article-title":"Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Gu\u00e9rin immunotherapy","volume":"104","author":"Ahirwar","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.09.026_bib0385","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-0039.1998.tb03002.x","article-title":"Polymorphism of the 5\u2032-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese","volume":"51","author":"Higuchi","year":"1998","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.eururo.2011.09.026_bib0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.arcmed.2010.03.005","article-title":"IL-8 \u2212251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort","volume":"41","author":"Ahirwar","year":"2010","journal-title":"Arch Med Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2006.06.009","article-title":"Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy","volume":"35","author":"Basturk","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.eururo.2011.09.026_bib0400","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13547500902818246","article-title":"Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy","volume":"14","author":"Ahirwar","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.eururo.2011.09.026_bib0405","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-5347(05)00653-1","article-title":"Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Gu\u00e9rin immunotherapy for superficial bladder cancer","volume":"175","author":"Decobert","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0410","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of response to bacillus Calmette-Gu\u00e9rin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0415","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0420","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0425","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-009-0673-z","article-title":"Recombinant bacillus Calmette-Gu\u00e9rin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2011.09.026_bib0430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","article-title":"Recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity","volume":"137","author":"Luo","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0435","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0022-5347(05)67417-4","article-title":"Murine IL-2 secreting recombinant bacillus Calmette-Gu\u00e9rin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2","volume":"164","author":"Yamada","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.09.026_bib0440","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","article-title":"Intravesical immunotherapy of superficial bladder cancer with chitosan\/interleukin-12","volume":"69","author":"Zaharoff","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0445","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2009.07.034","article-title":"MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers","volume":"387","author":"Wang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.eururo.2011.09.026_bib0450","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-09-1467","article-title":"MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival","volume":"15","author":"Mathe","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.09.026_bib0455","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-10-2530","article-title":"The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer","volume":"71","author":"Takei","year":"2011","journal-title":"Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811010992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811010992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T13:20:54Z","timestamp":1560777654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811010992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0302283811010992"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.09.026","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}